Cambium Oncology LLC
Publicly observedAtlanta, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Atlanta | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Cambium Oncology LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | FD2YFTNRQMK8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 May 2025Publicly observed
NIH SBIR/STTR award: Development of a Novel Armored CAR-T Immunotherapeutic for Pancreatic Cancer
USD 400,835.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant12 Jun 2024Publicly observed
NIH SBIR/STTR award: Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia
USD 1,050,003.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant12 Jun 2024Publicly observed
NIH SBIR/STTR award: Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia
USD 999,997.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.